Stryker (NYSE:SYK) Cash, Cash Equivalents, Marketable Securities

: $1,478 Mil (As of Jun. 2023)

View and export this data going back to 1988. Start your Free Trial

Stryker's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 ($1,928.00 Mil) to Mar. 2023 ($1,757.00 Mil) but then stayed the same from Mar. 2023 ($1,757.00 Mil) to Jun. 2023 ($1,478.00 Mil).

Stryker's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($3,024.00 Mil) to Dec. 2021 ($3,019.00 Mil) and declined from Dec. 2021 ($3,019.00 Mil) to Dec. 2022 ($1,928.00 Mil).

Stryker Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Stryker's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stryker Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

3,699.00

4,425.00

3,024.00

3,019.00

1,928.00

Stryker Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash, Cash Equivalents, Marketable Securities																1,127.00	1,497.00	1,928.00	1,757.00	1,478.00

Stryker Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Stryker (NYSE:SYK) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Stryker Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Stryker's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Stryker (NYSE:SYK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stryker Corp (NYSE:SYK) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

SYK:Mexico SYK:Germany S1YK34:Brazil SYK:Austria

Address

2825 Airview Boulevard, Kalamazoo, MI, USA, 49002

Website

https://www.stryker.com

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Executives

James Andrew Pierce	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Spencer S Stiles	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Giovanni Caforio	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Skeete Tatum Lisa M	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Robert S Fletcher	officer: VP, Chief Legal Officer	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Viju Menon	officer: Group President	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Sherilyn S Mccoy	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Rajeev Suri	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary K Brainerd	director	8170 33RD AVENUE SOUTH, BLOOMINGTON MN 55425
Graham A Mclean	officer: President, Asia-Pacific	1 CORPORATE AVENUE ROWVILLE, VICTORIA C3 3178
Glenn S Boehnlein	officer: Vice President, CFO	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
M Kathryn Fink	officer: VP, Global Human Resources	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Yin C Becker	officer: VP, Comm. & Public Affairs	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Bijoy Sagar	officer: VP, Chief Information Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Michael Damon Hutchinson	officer: General Counsel	2825 AIRVIEW BLVD, KALAMAZOO MI 49002